ZEISS Medical Technology has announced that it will showcase new digital AI tools and ‘revolutionary’ new surgical solutions at the American Academy of Ophthalmology (AAO) conference from Oct. 19-21, 2024, in Chicago.
Extending the ZEISS digital portfolio, the company will introduce ZEISS VisioGen, an AI-driven solution which it says designed to enhance refractive patient communication and streamline clinic operations, expanding the value to ophthalmologists and clinics by helping them grow their business through improved patient engagement.
ZEISS VisioGen leverages generative AI for effective and efficient patient acquisition-as-a-service. The software solution provides digital communication services to offer fast, high-quality responses to patients.
ZEISS says VisioGen enables clinics to respond more effectively to patient inquiries while converting more patients to consultations using the latest GenAI technology combined with substantiated and verified content from ZEISS to generate personalised draft responses to patient queries for clinical staff to finalise and use.
“ZEISS continues to expand its digital leadership in ophthalmology, offering new, pioneering ophthalmic offerings and clinical tools that create an enhanced digital workflow experience for both patients and surgeons,” said Euan S. Thomson, Ph.D., Head of the Digital Business Unit for ZEISS Medical Technology. “With the foundation of our Health Data Platform as part of the ZEISS Medical Ecosystem, our data-driven healthcare solutions unlock enormous value for surgeons, helping them deliver more efficient and personalised care throughout a patient’s journey.”
“ZEISS VisioGen is an extremely useful tool for the busy refractive practice. It can save time and prevent grammatical errors in responding to questions from potential patients. The response time is quick and useful. Responses can also be effectively tailored to the specifics of your individual practice,” said Dr. Luke Rebenitsch, MD, ClearSight, Oklahoma City (OK, USA).
Demonstrating its continued momentum in the LVC market, ZEISS recently celebrated that more than 10 million eyes have been treated with lenticule extraction solutions utilising ZEISS SMILE and ZEISS SMILE pro, marking a significant milestone for the company and proof of the growing international adoption of safe and effective lenticule extraction solutions.
ZEISS will also showcase the recently FDA-approved VISUMAX 800 with SMILE pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements as compared to the previous generation VisuMaxaccording to the company.
The VISUMAX 800 creates the lenticule in less than 10 seconds by using a higher laser pulse repetition rate of 2 MHz. ZEISS says the femtosecond laser also provides greater flexibility for the surgeon and patient, with a smaller footprint and compatibility with a variety of patient beds.
Recently FDA cleared and now broadly available in the U.S., ZEISS will also demonstrate the its ZEISS MICOR 700, a hand-held lens removal device with ultrasound-free operation, which the company says ‘reinvents’ lens extraction by providing a sustainable solution with a low initial investment to help surgeons expand their intraocular working space.
ZEISS will also showcase its expanded portfolio of high-end microscopes with the ZEISS ARTEVO 850 3D heads-up ophthalmic microscope, and the ZEISS ARTEVO 850 with CALLISTO eye that features a redesigned intuitive user interface that centralises all controls on a single touchscreen.
The second latest addition to ZEISS’s portfolio of optical surgical microscopes, the new ARTEVO 750, introduces advanced optical visualisation technology, including new RGB LED illumination with adjustable light colour temperature, as well as data overlays provided in the eyepiece with a 40% increase in resolution.
ZEISS is redefining the future of retinal care, offering a holistic approach that empowers specialists to deliver excellent patient care throughout the entire patient journey. At AAO, ZEISS will showcase its comprehensive portfolio across the entire ZEISS Retina Workflow, now combining cutting-edge diagnostic solutions with advanced visualisation and vitreoretinal surgical systems and next generation therapeutic lasers.
The ZEISS Retina Workflow offers connected and integrated solutions that help eyecare professionals to deliver optimised patient care from early detection, through monitoring, to in-office or surgical treatments.
ZEISS will showcase cutting-edge imaging technology and 3D visualisation as part of the ZEISS Retina Workflow. The CIRRUSs 6000 from ZEISS introduces an expanded Reference Database, triple that of its previous database, with greater diversity and three different disc sizes for more individualised patient care.
ZEISS says the newest addition to its Retina Workflow, the DORC EVA NEXUS surgical system and instrumentation bring added value and synergy to the operating room.
The DORC vitreoretinal portfolio includes the EVA NEXUS phacovitrectomy system featuring the VTi pump, offering FLOW and VACUUM fluidics, EVA AVETA trocar cannula system with Push-Fit HI-FLOW infusion connection, TDC (two-dimensional cutting) vitrectomy with cut speeds of up to 20,000 CPM, EVA INICIO microinjection system, and an extensive range of posterior instruments including 27G ULTRA for small-gauge surgery, as well as a range of highly purified posterior surgical liquids and tamponades.
In addition, the ‘next-gen’ therapeutic laser portfolio received 510k FDA clearance for two models, the VISULAS combi, which combines YAG and 532 modalities, and the standalone VISULAS green (532) laser.
NB: Ratingmania is a place to find the finest discounts on the internet and all the necessities.
Source url www.med-technews.com
Digital Health,artificial intelligence (AI),ZEISS Medical Technology,ophthalmology,medical devices,ZEISS VisioGen,Oliver Johnson,ZEISS Micor 700
